- Through its CLIA lab services, Grifols supports transfusion
medicine professionals analyzing some of the most complex donor and
patient blood typing cases.
- Grifols will also expand its program of free educational courses
for transfusion medicine professionals.
Company Website:
http://www.grifols.com
EMERYVILLE, Calif. -- (Business Wire)
Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare
company, has expanded the menu of tests offered at the Grifols
Immunohematology Center laboratory to include basic and advanced
serological and molecular testing. The Grifols Immunohematology Center,
located in San Marcos, Texas, offers extensive testing capabilities,
expert consulting, and classroom and laboratory-based educational
programs for transfusion medicine professionals. The lab’s main focus is
on analyzing some of the most complex cases related to donor and patient
blood typing, alloimmunization and hemolytic disease of the newborn.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161020006724/en/
Grifols Immunohematology Center laboratory in San Marcos, Texas, has expanded its testing capabilities to include basic and advanced serological and molecular testing. (Graphic: Business Wire)
“As a global leader in Transfusion Medicine, we pride ourselves on
understanding the unique testing and educational needs of this important
market segment,” said Brian Briggs, Vice President of North America
Sales & Marketing for the Grifols Diagnostics Division. “The expert
staff at our CLIA lab is excited to support blood banks, hospitals and
transfusion centers with a broad menu of serology and molecular tests –
including several advanced tests rarely performed at other reference
labs.”
Customers also benefit from Grifols Immunohematology Center’s access to
a collection of rare red cells, antibodies, and molecular variants from
around the world.
In 2017, Grifols will expand its program of free immunohematology
educational courses. These include Transfusion Science Educational
Courses (TSEC), interactive webinars, and hands-on workshops held at
locations throughout North America – all of which enable U.S.
transfusion medicine professionals to strengthen their expertise while
earning continuing education credits.
About Grifols
Grifols is a global healthcare company with more than 75 years of
history of improving people’s health and well-being through the
development of protein therapies, hospital pharmacy products and
diagnostic technology. The company is present in more than 100 countries
worldwide and its headquarters are located in Barcelona, Spain.
Grifols is a leader in plasma collection with a network of 160 plasma
donation centers in the U.S., and is a leading producer of
plasma-derived medicines. A recognized leader in transfusion medicine,
Grifols offers a comprehensive range of transfusion medicine,
hemostasis, and immunoassay solutions for clinical laboratories, blood
banks, and transfusion centers.
In 2015, sales exceeded EUR 3,934 million with a headcount close to
14,700 employees. Grifols demonstrates its commitment to advancing
healthcare by allocating a significant portion of its annual income to
R&D. The company’s class A shares are listed on the Spanish Stock
Exchange, where they are part of the Ibex-35 (MCE: GRF). Its non-voting
class B shares are listed on the Mercado Continuo (MCE: GRF.P)
and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information,
visit www.grifols.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006724/en/
Contacts:
Grifols US
Melinda Baker
510-915-3787
melinda.baker@grifols.com
Source: Grifols
© 2024 Canjex Publishing Ltd. All rights reserved.